Guardant Health, Cota Partner to Provide Clinicogenomic Cancer Data Resource for Biopharma

Original from: genomeweb

Real-world data firm Cota said Thursday that it has teamed up with Guardant Health to provide biopharmaceutical researchers access to a combined database that will include its own electronic health record data and Guardant’s genomic testing results from cancer patients.

The companies hope that the combined resource, with added AI analytics, will allow researchers to more easily understand and further validate correlations between molecular biomarkers, treatment decisions, and clinical outcomes. They also believe it could help optimize drug development, particularly via longitudinal liquid biopsy testing data, allowing drugmakers to study how different genomic subgroups respond to therapies over time in real-world settings.

"Giving biopharmaceutical researchers the ability to connect detailed information about tumor biology and therapy response with real-world patient outcome data will expedite the discovery of new biomarker-based therapies for patients and make the drug development process more economical, as well," Guardant Health Chief Medical Officer Craig Eagle said in a statement.

Guardant noted that its testing datasets span various disease stages from initial tumor profiling for therapy selection to recurrence and response monitoring. Cota described its own offering as including curated data that track a patient’s complete cancer care journey, drawing from both academic and community care center settings.

Source: Guardant Health, Cota Partner to Provide Clinicogenomic Cancer Data Resource for Biopharma